Nothing said here yet.
to join the conversation.
| Lin Shao-LeeChief Executive Officer | Sell | 10,000 | $275.0K | Mon, Oct 12 |
| Ray SumitaChief Legal Compliance Officer | Sell | 1,844 | $51.7K | Mon, Oct 12 |
| Meluzio Michael VincentVP, Prin. Accounting Officer | Sell | 1,144 | $32.1K | Mon, Oct 12 |
| Lin Shao-LeeChief Executive Officer | Sell | 1,087 | $30.5K | Mon, Oct 12 |
| Ray SumitaChief Legal Compliance Officer | Sell | 6,442 | $195.5K | Thu, Aug 13 |
| Meluzio Michael VincentVP, Prin. Accounting Officer | Sell | 4,106 | $124.6K | Thu, Aug 13 |
| Ray SumitaChief Legal Compliance Officer | Sell | 2,383 | $70.0K | Thu, Aug 13 |
| Meluzio Michael VincentVP, Prin. Accounting Officer | Sell | 1,519 | $44.6K | Thu, Aug 13 |
| Ray SumitaChief Legal Compliance Officer | Sell | 4 | $124 | Thu, Aug 13 |
| Meluzio Michael VincentVP, Prin. Accounting Officer | Sell | 3 | $93 | Thu, Aug 13 |
Cue Biopharma (NASDAQ:CUE) reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines.
Cue Biopharma, Inc. (NASDAQ:CUE) reported positive Phase 2 results for CUE-221 on September 20.
Cue Biopharma (NASDAQ:CUE) shares rose 41. 6% in premarket trading after the company reported positive topline results from a Phase 2 clinical trial evaluating CUE-221 in patients with moderate to severe chronic spontaneous urticaria.
Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling study Results support potential for differentiated clinical impact for patients suffering from chronic…
Announced recent Investigational New Drug (IND) submission to the FDA for CUE-221 in food allergy applicationsCompleted a $50 million private placement (PIPE) to further fund clinical development and the portfolio with significant potential for…
Veteran biotech finance executive joins Cue to support the Company’s next phase of clinical and corporate growth as the company advances regulatory filing for food allergyBOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.
Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseasesBOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.
BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.